corticorelin ovine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5195 | 79804-71-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
used in diagnosis of adrenocortical insufficiency & Cushing's syndrome; AA sequence given in first source; MF C205-H339-N59-O63-S; RN given refers to triflutate salt; RN for parent cpd not avail 3/94
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 23, 1996 | FDA | FERRING |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:33295 | diagnostic aid |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.12 | acidic |
| pKa2 | 3.45 | acidic |
| pKa3 | 3.7 | acidic |
| pKa4 | 4.05 | acidic |
| pKa5 | 4.3 | acidic |
| pKa6 | 4.88 | acidic |
| pKa7 | 11.87 | acidic |
| pKa8 | 12.28 | acidic |
| pKa9 | 12.46 | acidic |
| pKa10 | 12.47 | acidic |
| pKa11 | 12.61 | acidic |
| pKa12 | 12.75 | acidic |
| pKa13 | 12.83 | acidic |
| pKa14 | 12.99 | acidic |
| pKa15 | 13.1 | acidic |
| pKa16 | 13.14 | acidic |
| pKa17 | 13.18 | acidic |
| pKa18 | 13.28 | acidic |
| pKa19 | 13.33 | acidic |
| pKa20 | 13.44 | acidic |
| pKa21 | 13.52 | acidic |
| pKa22 | 13.54 | acidic |
| pKa23 | 13.58 | acidic |
| pKa24 | 13.6 | acidic |
| pKa25 | 13.7 | acidic |
| pKa26 | 13.75 | acidic |
| pKa27 | 13.86 | acidic |
| pKa28 | 13.87 | acidic |
| pKa29 | 13.89 | acidic |
| pKa30 | 13.91 | acidic |
| pKa31 | 11.38 | Basic |
| pKa32 | 10.97 | Basic |
| pKa33 | 10.59 | Basic |
| pKa34 | 10.18 | Basic |
| pKa35 | 7.66 | Basic |
| pKa36 | 6.99 | Basic |
| pKa37 | 6.39 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| Y124TZ0513 | UNII |
| 121249-14-7 | SECONDARY_CAS_RN |
| 4021062 | VANDF |
| 4024084 | VANDF |
| C0251516 | UMLSCUI |
| CHEBI:65307 | CHEBI |
| 16132344 | PUBCHEM_CID |
| DB09067 | DRUGBANK_ID |
| D03592 | KEGG_DRUG |
| CHEMBL1201591 | ChEMBL_ID |
| 4505 | MMSL |
| 6021 | MMSL |
| 006761 | NDDF |
| 007306 | NDDF |
| 109205007 | SNOMEDCT_US |
| 398935003 | SNOMEDCT_US |
| 74670 | RXNORM |
| C085671 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Acthrel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55566-0302 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 ug | INTRAVENOUS | BLA | 19 sections |